MedTrace Logo

A Phase 1 Study of KHN707 Tablets in Healthy Participants

NCT07557537 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-04-29

No results posted yet for this study

Summary

This is a single-center, randomized, double-blind, placebo-controlled study . The objective is to evaluate the safety , tolerability and PK profile of KHN707 tablets in Chinese healthy participants.

Conditions

  • Healthy Adult Participants

Interventions

DRUG

KHN707 tablet

Participants will receive a single dose or two doses of KHN707 tablets orally in a fasting or fed state.

DRUG

Placebo

All participants will receive a single dose or two doses of the placebo in a fasting or fed state.

Sponsors & Collaborators

  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2026-10-31
Completion
2026-10-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07557537 on ClinicalTrials.gov